-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Increasing Understanding about the Role Biosimilar Agents Play in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 2 of 2)
In September 2017, the US Food and Drug Administration (FDA) approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename. Although bevacizumab-awwb is the only biosimilar agent specific to lung cancer, there are many in development, necessitating a firm understanding of the regulatory approval process and cost comparators for these agents.…
-
Fiona Blackhall: Breaking new ground in small-cell lung cancer
Liquid biopsies have also opened new perspectives in the field to which Blackhall has dedicated much of her research career. “I would like to use this award to highlight the unmet need in small-cell lung cancer, where progress has lagged behind non-small cell lung cancer in the last decade, partly because of the difficulty of…
-
Johan Vansteenkiste: A lifelong commitment to improving outcomes in thoracic oncology
Vansteenkiste leads the Respiratory Oncology Unit at University Hospitals Leuven, where he has been involved in approximately 300 lung cancer trials. He has served on the editorial boards of numerous peer-reviewed journals during his decades-long career, including a current position as associate editor for Annals of Oncology. Among other achievements, Vansteenkiste conducted benchmark-setting research into…
-
Ensuring Quality of Life During Lung Cancer Survivorship Requires a Multidisciplinary Team
Lung cancer is one of the most common cancers worldwide, with more than 2 million people diagnosed each year.1 Advances in early detection and treatment have resulted in more people surviving the disease. Nevertheless, in the United States, the overall 5-year survival rate is only 19% for all stages combined. However, in patients with localized…
-
COVID-19 and Lung Cancer: A Call for Immediate Action
The COVID-19 pandemic has had a devastating effect on lung cancer outcomes in the United Kingdom (UK). Fewer people have presented or have been referred for investigation, and those who do present have a more unfavorable stage. In October 2020, the Lung Cancer Coalition (UKLCC) published a report setting out a number of recommendations for…
-
A Clinical Trial of PD-L1 Inhibitor Durvalumab and PARP Inhibitor Olaparib for Patients With EGFR-Mutated Transformed SCLC
Discovery of targetable genomic alterations, including mutations of EGFR, have resulted in improved survival for patients with non-small cell lung cancer (NSCLC).1 Although many patients experience robust responses to EGFR-targeted therapy, acquired drug resistance is almost inevitable. Small cell lung cancer (SCLC) transformation as a mechanism of acquired resistance is reported in up to 14%…
-
Mitigating Pain in Thoracic Surgery
A middle-aged woman walks into the clinic using her right hand to hold her shirt away from her chest. “Even just my shirt brushing against my skin hurts,” she says with a grimace. The patient is now 4 months out from a thoracoscopic right upper lobectomy for early-stage NSCLC. She continues to report sharp pain…
-
The Dandelion Dilemma of Brain Metastases: Treating the Whole Lawn or the Weeds Separately
Approximately, 40% to 60% of patients with small cell lung cancer (SCLC) develop brain metastases (BMs),1 ,2 ,3 and fewer than 15% survive beyond 2 years.4 ,5 Whereas upfront stereotactic radiosurgery (SRS) has become the preferred treatment for brain metastases arising from most solid tumor histologies,6 SCLC remains an exception where whole brain radiotherapy (WBRT)…
-
New IASLC Grading System for Pulmonary Adenocarcinoma Proposed
Tumor grading is an important component of a pathology report, as it has been traditionally used as a prognostic indicator. For many tumors, grading is also used to help with case management and patient treatment, such as for breast, prostate, and urothelial carcinomas. Grading is based on a pattern or patterns of tumor growth (the…
-
Brendon Stiles, MD
Formerly an associate professor of cardiothoracic surgery at Weill Cornell Medicine, Brendon Stiles, MD, is now Chief of Thoracic Surgery and Surgical Oncology and Associate Director of Surgical Services for the Montefiore-Einstein Cancer Center, New York City. Dr. Stiles is looking forward to new opportunities to meaningfully address disparities in care and to reach out…